PubMed HealthSearch

Biomedical subjects

V Chabot

Publications and source records attributed to V Chabot.

11 recordsLinked to original sources

[Control of diabetes and late complications].

When insulin was introduced in medical therapy in 1922, it permitted to save diabetics from premature death; however, it has allowed, after a certain period of time, for the appearance of a cohort of chronic complications connected more or less specifically to the degree of hyperglycemia. After a short review of the pathophysiology of the microangiopathy, the authors have tried to demonstrate, on the basis of numerous prospective and retrospective studies in the human as well as in the animal, that an important relationship exists between the degree of glycemic control and the severity of the classical complications, retinopathy, neuropathy and nephropathy. However, the most recent studies have stressed the role of some other factors, not well established in the past, as for example the potential negative impact on retinopathy of rapid normalization of glycemia, following a long period of poor metabolic control. Likewise, high blood pressure, smoking, genetic background, as well as probably also excess of protein intake, do play an important etiopathogenic role. Thus, the simplistic equation hyperglycemia = complications is not completely valid. Microangiopathic risk in insulin-dependent diabetics seems to be low as long as their HbAlc is below 7.5%, and they do not have hypertension and do not abuse tobacco. Finally, the general approach to therapy is redefined: Try to get as close as possible to near-normoglycemia by multiple insulin injections, without causing, however, major hypoglycemia; this should be done very early after the onset of the disease.(ABSTRACT TRUNCATED AT 250 WORDS)

Animals

[Metabolic effects of gliclazide in diabetes type II patients. Study with indirect calorimetry].

An attempt is made to determine the effect of treatment with gliclazide on the manner in which obese patients with noninsulin-dependent diabetes dispose of an oral glucose load. Six patients were studied on two occasions - once after one month of an isocaloric diet containing 40% carbohydrate, and two months after gliclazide had been added. Body weight remained constant throughout the three months. However, fasting plasma glucose concentration fell and mean (+/- SEM) incremental insulin response to oral glucose increased significantly (p less than 0.05) with drug therapy (51.1 +/- 14.6 microU/ml vs 17.1 +/- 1.5 microU/ml). Glucose oxidation significantly improved after gliclazide treatment (16.9 +/- 2.4 g/3 h vs 7.5 +/- 2.1 g/3 h, p less than 0.02) in parallel with the fall in plasma glucose and the increase in insulin response. In addition, glucose storage significantly increased after drug therapy (44.1 +/- 10.1 g/3 h vs 28.4 +/- 7.2 g/3 h, p less than 0.001). In contrast, lipid oxidation fell with gliclazide treatment (7.2 +/- 0.7 g/2 h vs 12.0 +/- 1.7 g/3 h, p less than 0.02). This effect may be explained by improvement of the antilipolytic effect of insulin. In conclusion, improvement in glucose oxidation (25%) and in glucose storage (55%), together with reduced lipid oxidation, was observed after two months of gliclazide therapy.

Blood Glucose

[Diabetes mellitus: the role of metabolic control in the prevention of complications].

Recent studies have cast doubt on the idea, generally agreed but not unequivocally proven, that optimal control of diabetes could delay or prevent the development of late microangiopathic complications of the disease. In particular, a perfect equilibration of glycemic values could, in certain cases, deteriorate, rather than improve, the situation (pre-proliferative retinopathy). Through a review of literature the authors try to answer the following questions: is diabetic microangiopathy due to hereditary factors? Can the treatment of diabetes influence the appearance of late "triopathic" complications? If yes, could an optimal metabolic control result in a stop or a regression of these lesions? Based on the available data, the authors reach the conclusion that yes, it is worthwhile to treat correctly diabetes mellitus and, if possible, a perfect glycemic control should be sought. There are only few and well determined exceptions to this rule. In insulin dependent diabetics a perfect control can presently be obtained by means of conventional intensified insulin treatment (multiple injections) or of continuous subcutaneous insulin infusion (insulin pump) for variable periods of time.

Animals